| 134427 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
Water Microbiology Scheme - (QWAS)
Water Microbiology Scheme - (QWAS)
|
2021-03-01 |
|
|
| Tested property |
(SARS-CoV-2) (Detection of SARS-CoV-2) (Optional quantification of SARS-CoV-2 (Trial)) |
| Testing method |
(2 x 1.5 ml vial (A & B) of non-infectious, SARS-CoV-2 virus (whole genome) 1 x >100ml sterile water diluent 1 x >20g sterile sludge matrix) |
|
| 1271562 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus serology: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG-, IgG-S, IgG-N, IgM, IgA, total antibody) |
| Scheme name in national language |
(Vírus szerológia: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-S (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-N (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgM (OD, S/CO, quantitative, evaluation)) |
|
| 1271426 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus nucleic acid determination: SARS-CoV-2) |
| Remarks |
(amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus. Qualitative results are) |
| Scheme name in national language |
(Vírus nukleinsav meghatározás: SARS-CoV-2) |
|
| 1169419 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Immunology – SARS-CoV-2 (Ab) (416)
[Virusimmunologie - SARS-CoV-2 (Ak) (416)]
Virus Immunology – SARS-CoV-2 (Ab) (416)
[Virusimmunologie - SARS-CoV-2 (Ak) (416)]
|
2025-11-20 |
|
|
| PT name |
(Virus Immunology – SARS-CoV-2 (Ab) (416)) |
| Scheme name in national language |
(Virusimmunologie - SARS-CoV-2 (Ak) (416)) |
| Tested property |
(Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM)) (Anti-SARS-CoV-2 IgG) (Anti-SARS-CoV-2 IgG avidity (not certified)) (Anti-SARS-CoV-2 IgA (not certified)) (Anti-SARS-CoV-2 IgM (not certified)) |
|
| 1163345 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
|
2025-11-20 |
|
|
| PT name |
(Virus Genome Detection – SARS-CoV-2 sequence analysis (417)) |
| Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)) |
| Tested property |
(Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing) |
|
| 1163338 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
|
2025-11-20 |
|
|
| PT name |
(Virus Genome Detection – SARS-CoV-2 (409)) |
| Remarks |
(The sample set contains defined samples with SARS-CoV-2 (full virus, inactivated).
The) |
| Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 (409)) |
| Tested property |
(Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2) |
|
| 1163321 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
|
2024-04-16 |
|
|
| Tested property |
(influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated)) |
|
| 1163304 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
|
2024-04-16 |
|
|
| Tested property |
(incl. avian influenza A viruses, parecho, parainfluenza, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively) |
|
| 437169 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Coronaviruses incl. SARS-CoV-2 (340)
[Virusgenom-Nachweis – Coronaviren inkl. SARS-CoV-2 (340)]
Virus Genome Detection – Coronaviruses incl. SARS-CoV-2 (340)
[Virusgenom-Nachweis – Coronaviren inkl. SARS-CoV-2 (340)]
|
2025-11-19 |
|
|
| PT name |
(Virus Genome Detection – Coronaviruses incl. SARS-CoV-2 (340)) |
| Scheme name in national language |
(Virusgenom-Nachweis – Coronaviren inkl. SARS-CoV-2 (340)) |
| Tested property |
(Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV) (Option for differentiaton between SARS-CoV-2, MERS-CoV and other human coronaviruses (samples which) (contain SARS-CoV-2 and MERS-CoV, repectively, are inactivated) |
|
| 1160040 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Antigen Detection – SARS-CoV-2 (Ag) (410)
[Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)]
Virus Antigen Detection – SARS-CoV-2 (Ag) (410)
[Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)]
|
2025-11-20 |
|
|
| PT name |
(Virus Antigen Detection – SARS-CoV-2 (Ag) (410)) |
| Remarks |
(The sample set contains defined samples with antigen from SARS-CoV-2 (inactivated).
For POCT) (samples are suitable for rapid tests and automated immunoassays for the detection of SARS-CoV-2) |
| Scheme name in national language |
(Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)) |
| Tested property |
(SARS-CoV-2 antigen) |
|
| 699949 |
United Kingdom |
UK NEQAS for Immunology, Immunochemistry & Allergy
UK NEQAS for Immunology, Immunochemistry & Allergy
|
UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies
UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies
|
2023-05-30 |
|
|
| PT name |
(UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies) |
| Tested property |
(SARS-CoV-2 / COVID-19 Antibodies) |
|
| 706310 |
Portugal |
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
|
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
|
2024-03-13 |
|
|
| PT name |
(SARS-CoV-2, molecular detection) |
| Scheme name in national language |
(SARS-CoV-2, molecular detection) |
| Tested property |
(SARS-CoV-2 virus) |
|
| 824901 |
Germany |
Reference Institute for Bioanalytics
Reference Institute for Bioanalytics
|
SARS-CoV-2 Immunology
[SARS-CoV-2 Immunologie]
SARS-CoV-2 Immunology
[SARS-CoV-2 Immunologie]
|
2021-02-16 |
|
|
| PT name |
(SARS-CoV-2 Immunology) |
| Scheme name in national language |
(SARS-CoV-2 Immunologie) |
| Tested property |
(Anti-SARS-CoV-2 IgG, Anti-SARS-CoV-2 IgA) |
|
| 883284 |
Thailand |
Department of Medical Sciences PT provider (DMSc PT provider)
Department of Medical Sciences PT provider (DMSc PT provider)
|
SARS-CoV-2 detection by Real-time RT-PCR
[SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)]
SARS-CoV-2 detection by Real-time RT-PCR
[SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)]
|
2024-01-09 |
|
|
| PT name |
(SARS-CoV-2 detection by Real-time RT-PCR) |
| Scheme name in national language |
(SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)) |
|
| 1129430 |
Spain |
ielab
ielab
|
SARS-CoV-2
[SARS-CoV-2]
SARS-CoV-2
[SARS-CoV-2]
|
2023-11-29 |
|
|
| PT name |
(SARS-CoV-2) |
| Scheme name in national language |
(SARS-CoV-2) |
| Tested property |
(SARS-CoV-2) |
|
| 1050992 |
France |
CTCB
CTCB
|
RNA SARS-CoV2 (virology)
[ARN SARS-CoV2 (virologie)]
RNA SARS-CoV2 (virology)
[ARN SARS-CoV2 (virologie)]
|
2023-05-24 |
|
|
| PT name |
(RNA SARS-CoV2 (virology)) |
| Scheme name in national language |
(ARN SARS-CoV2 (virologie)) |
| Test item |
(Detection of SARS-CoV2 RNA) |
| Tested property |
(ARN SARS-CoV2 - cell culture supernatant) |
|
| 1217643 |
United Kingdom |
UK NEQAS for Microbiology
UK NEQAS for Microbiology
|
Respiratory viruses Point of Care
[Respiratory viruses Point of Care]
Respiratory viruses Point of Care
[Respiratory viruses Point of Care]
|
2024-09-24 |
|
|
| Tested property |
(Detection of antigens /nucleic acid for SARS-CoV-2, influenza and RSV using POCT devices) |
|
| 1271523 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(POCT: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG, IgM, total antibody) and antigen determination) |
| Scheme name in national language |
(POCT: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total qualitative) (Anti-SARS-CoV-2 - IgG qualitative) (Anti-SARS-CoV-2 - IgM qualitative) (SARS-CoV-2 Antigen qualitative) (SARS-CoV-2 interpretation) |
|
| 790376 |
Australia |
RCPAQAP
RCPAQAP
|
PoCT: COVID-19 serology (IgG/IgM)
PoCT: COVID-19 serology (IgG/IgM)
|
2020-10-26 |
|
|
| PT name |
(PoCT: COVID-19 serology (IgG/IgM)) |
| Tested property |
(COVID-19 Serology) |
|
| 1144039 |
United Kingdom |
Weqas
Weqas
|
POCT Respiratory Virus
[POCT Respiratory Virus]
POCT Respiratory Virus
[POCT Respiratory Virus]
|
2026-04-20 |
|
|
| Remarks |
(targeted for Influenza A (and subtypes) Influenza B, SARS-Cov-2, and Respiratory Syncytial Virus) (buffer which may contain Influenza A (either / both H1N1 and H3N2 subtypes), influenza B, RSV, SARS) (supplied ready to use; no pre-analytical preparation is required.
- Qualitative reporting for SARS-CoV-2) |
| Tested property |
(SARS-CoV-2 Ag (RNA)) |
|
